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ABSTRACT
Background: Human Papillomavirus (HPV) subtypes are the primary cause of cervical cancer. Despite introduction of the
HPV vaccine in 2006, vaccination percentages remain low across Georgia counties. The primary objective of this research
was to conduct a descriptive epidemiological study of HPV vaccination coverage among individuals in the South Central
Health District (SCHD) to provide guidance for targeted vaccination campaigns aimed at adolescents residing in rural
communities.
Methods: Data from the Georgia Registry of Immunization Transactions and Services and AEGIS.net, Inc. were used to
analyze demographic and socioeconomic factors associated with HPV vaccine uptake among individuals visiting county
health departments in the SCHD from 2007-2014. Descriptive statistics were used to evaluate the relationship between sex,
age at first vaccination, county of vaccine administration, race, and insurance status to vaccine series completion.
Results: In the SCHD, Johnson County had the highest completion percentage (50%); Montgomery County had the lowest
(20%). However, Montgomery County had the fastest time to completion (334 days). Throughout the district, males were fully
vaccinated at much lower percentages than females (p < 0.001). Race was a significant variable (p=0.011) for vaccine
completion. Compared to other racial groups, more White individuals completed the HPV vaccine. Absolute counts of HPV
vaccine doses peaked in the study population during 2010 (n=507).
Conclusions: Due to overall low rates, community-based intervention methods should be considered to increase HPV vaccine
uptake across the SCHD. School-based programs may be useful in targeting at-risk populations and increasing rates of HPV
vaccine initiation and completion. Expanded efforts are needed to determine the best structure for effective school-based
programs.
Key Words: human papillomavirus (HPV); HPV vaccine; HPV vaccine completion; adolescent; HPV vaccine initiation; rural
health
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the most common complaint being pain at the injection site,
which resolves shortly after injection (Denny, International
Federation of Gynecology and Obstetrics, 2013). Safety of
the HPV2 vaccine has been monitored largely by the
PATRICIA trial (Lehtinen, Paavonen, Wheeler, et al., 2012)
and the Costa Rica vaccine trial (Herrero, Hildesheim,
Rodríguez, et al., 2008); the HPV4 vaccine has been
assessed by the FUTURE I and FUTURE II trials
(McCormack, 2014), all with results suggesting adequate
vaccine safety (De Vincenzo, Conte, Ricci, et al., 2014).
The efficacy of the HPV2 and HPV4 vaccines has also been
assessed in trials. Both prevent 90-100% of new HPV 16
and 18 infections and associated grade 2 or higher cervical
intraepithelial neoplasia, which are potentially premalignant
transformations, in women not already infected with HPV
16 or 18 at the time of vaccination (Herrero, González,
Markowitz, 2015). Antibodies have remained at consistently

INTRODUCTION
An association between human papillomavirus (HPV) and
cervical cancer has been established. Two HPV-subtypes,
16 and 18, contribute to most cervical cancer cases
(Doorbar, Quint, Banks, et al., 2012; Walboomers, Jacobs,
Manos, et al., 1999). These subtypes are also the cause of
penile, vaginal, vulvar, oropharyngeal and anal cancers
(Bonafide, Vanable, 2015; Backes, Kurman, Pimenta, et al.,
2009). Despite introduction of an HPV vaccine in 2006,
average vaccination percentages remain low. Nationally,
only 37.6% of female and 13.9% of male adolescents aged
13-17 years received greater than or equal to 3 doses of the
HPV vaccine (CDC, 2014).
Both the bivalent (HPV2) and quadrivalent (HPV4)
vaccines have received positive safety profile reviews with
http://www.gapha.org/jgpha/
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high levels for nearly 10 years, indicating that the vaccines
remain effective for long periods (McCormack, 2014; Naud,
Roteli-Martins, De Carvalho, et al., 2014). Despite evidence
that the HPV vaccine is safe, effective, and long lasting,
vaccination percentages remain low (CDC, 2014).

METHODS
Data Sources
Information from the AEGIS.net, Inc. (AEGIS) and the
Georgia Registry of Immunization Transactions and
Services (GRITS) databases from 2007-2014 were utilized.
AEGIS is an intergovernmental health information database
that documents health records of clients who sought services
provided by the SCHD county health departments. GRITS,
a registry managed by the Georgia Department of Public
Health, includes complete and current vaccination records
from across the state. Clients who received at least one dose
of HPV vaccine from a county health department in the
SCHD during this time frame were identified from AEGIS.
GRITS was then used to measure vaccine series completion
of the SCHD clients in case vaccine doses were
administered outside of the SCHD. The Augusta University
Institutional Review Board approved this study.

Safety, effectiveness, and duration of the vaccine, as well as
uncertainty about when to return for subsequent doses, were
commonly cited as reasons not to receive the vaccine
(Krawczyk, Perez, King, et al., 2015; Moore, Crosby,
Young, et al., 2010; Printz, 2013). Further, participants who
did not intend to receive the HPV vaccine cited vaccine
safety and low perceived need as their motivating reasons;
those intending to receive the vaccine cited practical
concerns, such as cost, as barriers to receiving vaccination
(Gerend, Shepherd, Shepherd, 2013). One study consistent
with the Information-Motivation-Behavioral Skills model
suggested that well-informed individuals who were
motivated to act on their knowledge of the HPV vaccine and
possess the behavioral skills necessary to overcome the
barriers of vaccination would complete the HPV vaccine
series (Fisher, Fisher, Harman, 2003; Fisher, 2012). In
alignment with the Health Belief Model, HPV vaccine
acceptability was higher when people believed that the
vaccine was effective, a physician recommended it, and
HPV infection was likely (Becker, 1974; Brewer, Fazekas,
2007).

Data Variables
By use of AEGIS and GRITS, this research examined age,
race, sex, and insurance status as key independent variables
of HPV vaccine uptake due to their acknowledged relevance
(CDC, 2014) and their availability in the administrative
databases. The following variables were evaluated: reported
county of HPV vaccine administration in the SCHD
(Bleckley/ Dodge/ Johnson/ Laurens/ Montgomery/ Pulaski/
Telfair/ Treutlen/ Wheeler/ Wilcox), age at first vaccination,
race (Asian/Black/Native Hawaiian and Other Pacific
Islander/Multiracial/American
Indian
and
Alaska
Native/Unknown/White), sex (male/female/unknown), and
insurance status at the most recent visit to the SCHD
(yes/no/unknown). Anyone who received at least one HPV
vaccine dose in the SCHD was recorded and completion
was defined as having received at least three HPV vaccine
doses.

Though these generalized determinants of HPV vaccination
have been helpful, a more in-depth analysis at the countylevel is needed in order to understand disparities in HPV
vaccine uptake and to identify specific populations who are
at risk for not receiving the vaccine. Within the state of
Georgia, only 33.2% of female and 15.3% of male
adolescents aged 13-17 years received greater than or equal
to 3 doses of the HPV vaccine (CDC, 2014). This finding
reveals that female vaccination in Georgia falls below the
national average of 37.6%, and that male vaccination is
slightly greater than the national average of 13.9% (CDC,
2014). The impact of low vaccination rates is seen through
health disparities related to the higher incidence of cervical
cancer in southern states, including Georgia, compared to
other states (Markowitz, Dunne, Saraiya, et al., 2007).
Health disparities, particularly in rural areas of the state,
may be explained by a combination of culture, economy,
and geographical location (Thomas, DiClemente, Snell,
2014). Furthermore, a lack of information about sexual and
reproductive health in rural communities can lead to
parental mistrust and further healthcare disparities (Thomas,
Strickland, Diclemente, et al. 2013).

Data Analysis
The data provided by AEGIS and GRITS were used to
examine vaccine completion percentages, defined as
receiving all three injections in the series, among SCHD
clients over time and across counties. A chi-square test for
independence analyzed the relationships between
categorical variables when each category had at least 5
values; otherwise; a Fisher’s exact test was employed. For
the continuous variable, age at first vaccination, a t-test was
utilized. Counts and percentages were displayed where
appropriate. All analyses were conducted using Stata
(StataCorp, 2007) with a p-value of < 0.05 level of
significance.

The focus of the present study was on the South Central
Health District (SCHD) of Georgia, a rural public health
district comprised of 10 counties. The objective was to
conduct a descriptive epidemiological study of HPV
vaccination coverage among individuals in the SCHD to
provide guidance for targeted vaccination campaigns aimed
at adolescents residing in rural communities. This study
examined the relationship between demographic and
socioeconomic factors to completion of HPV vaccination.

http://www.gapha.org/jgpha/

RESULTS
From 2007 to 2014, county health departments within the
SCHD provided at least one dose of vaccine in the HPV
series to 2,362 clients throughout the district. Overall, 945
(40%) completed the entire HPV vaccine series. Table 1
shows demographic and socioeconomic characteristics of
clients who received at least one dose of HPV vaccine
through a health department in the SCHD during this time
period. Similar to statewide data, the proportion of females
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who completed the HPV vaccine series was significantly
greater than that for males (p < 0.001). Additionally, the
distribution across counties was significantly different (p <
0.001) in regard to completion status. In the SCHD data,
race was a significant variable in regard to vaccine series
completion (p=0.011) with a larger proportion of white

clients completing the series compared to other racial
groups. The presence or absence of insurance was not
significantly associated with vaccine series completion
(p=0.441).

Table 1. Demographic and socioeconomic factors associated with completion of the HPV vaccine in the SCHD of
Georgia (AEGIS, GRITS 2007-2014)
Series Incomplete
(1417, 60%)

Variable

Age at 1st Vaccination*
Sex
Male
Female
Unknown
County
Bleckley
Dodge
Johnson
Laurens
Montgomery
Pulaski
Telfair
Treutlen
Wheeler
Wilcox
Race
Asian
Black
Native Hawaiian/Other Pacific Islander
Multiracial
American Indian/Alaska Native
Unknown
White

Series Complete
(945, 40%)

p-value

Mean

Std. Dev.

Mean

Std. Dev.

12.0

0.1

12.0

0.1

Number

Percentage

Number

Percentage

280
1133
4

19.8
80.0
0.3

85
858
2

9.0
91.0
0.2

< 0.001

71
67
170
321
222
76
262
54
64
110

5.0
4.7
12.0
22.7
15.7
5.4
18.5
3.8
4.5
7.8

61
39
174
185
49
30
248
45
47
67

6.5
4.1
18.4
19.6
5.2
3.2
26.2
4.8
5.0
7.1

< 0.001

9
696
0

0.6
49.1
0.0

2
417
1

0.2
44.1
0.1

0.011

10
4
6
692

0.7
0.3
0.4
48.8

14
0
3
508

1.5
0.0
0.3
53.8

747
42
156

79.1
4.4
16.5

Insurance
Yes
1092
77.1
No
62
4.4
Unknown
263
18.6
*All unknown or missing values for age were removed resulting in n=2339.

0.054

0.441

Table 2. Number of HPV vaccine doses received by sex in the SCHD (AEGIS, GRITS 2007-2014)
Number of HPV
Vaccines Received
1
2
3

Number
191
89
85

Males
(n=365)
Percentage
52.3
24.4
23.3

After excluding six subjects with unknown sex status, the
association between sex and number of HPV vaccine doses
received was determined (Table 2). Data relating to the
number of subjects who did not receive HPV vaccination
in the SCHD were not available. Among those who
received at least one HPV vaccine dose in a SCHD county
http://www.gapha.org/jgpha/

Females
(n=1,991)
Number
Percentage
663
33.3
470
23.6
858
43.1

health department, females were more likely to receive all
three HPV vaccine doses (43.1%) compared to males, who
were more likely to receive only one (52.3%) (p-value <
0.001).
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The number of individuals in the SCHD who received their
1st vaccine dose from 2007-2014 is shown in Figure 1.
Four individuals were excluded due to receiving their first
vaccine dose outside of the evaluation period according to

the GRITS database. A peak in initial HPV vaccinations
was evident for 2010. However, initial HPV vaccinations
in the study population declined in 2011 and remained low.

Figure 1. Individuals in the South Central Health District who initiated the HPV vaccine series by year
(AEGIS, GRITS 2007-2014)

Figure 2 highlights the percentages of vaccine series
completion by county among individuals who received at
least one vaccine dose at a county health department in the
SCHD from 2007-2014. In Johnson County, the county
with the highest completion percentage, more than 50% of
individuals who received an HPV vaccination completed

http://www.gapha.org/jgpha/

the series. In contrast, in Montgomery County, fewer than
20% of individuals who received at least one HPV
vaccination at the SCHD completed the series. Overall,
there was variety in HPV completion percentages across
the counties in the SCHD.
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Figure 2. Completion percentage among individuals who received at least one HPV vaccine dose
through the SCHD by county (AEGIS, GRITS 2007-2014)

Among individuals who completed the HPV vaccine series,
the average times to completion across counties served by
the SCHD were determined (Figure 3). Montgomery
County, at 334 days, had the fastest average series
completion time; Wilcox County, at 800 days, had the

slowest. Thus, Montgomery County had the lowest
completion percentages in the SCHD, but individuals in
Montgomery County who completed the HPV vaccine
series did so quickly.

Figure 3. Average time to completion among individuals in the SCHD who completed the
vaccine series by county (AEGIS, GRITS 2007-2014)

http://www.gapha.org/jgpha/
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parental acceptance of HPV vaccination found that parental
opinion on severity of illness and intent to vaccinate
adolescents correlated with parental acceptance of school
programs, indicating a need for parental education in regard
to the importance of the HPV vaccine (Gargano, Weiss,
Underwood, et al., 2015). Through further assessment of
school-based programs, rural health districts could develop
vaccine campaigns best suited to their target population.

DISCUSSION
In the SCHD, males were fully vaccinated at lower
percentages than females. Additionally, in 2010, an increase
in vaccine delivery was evident across the study population.
This increase was followed by a decline in the years
following. On average, the completion percentage in each
county in this SCHD subpopulation appeared to be higher
than the statewide measure, but was still low. The results for
vaccine completion reflect race as a significant variable in
the SCHD.

Strengths of this study included the fact that, to conduct a
comprehensive edpidemiological assessement of this rural
population, data were gathered from two sources, GRITS
and AEGIS. By utilizing GRITS data, this research allowed
inclusion of vaccine data from people who received
additional HPV vaccine doses outside of the SCHD.
Additionally, this study used a methodological approach to
provide
evidence-based
recommendations
for
a
predominately rural population in Georgia. The results led
to a better understanding of the demographic and
socioeconomic characteristics associated with HPV vaccine
uptake in rural areas.

Since rural residence is negatively associated with HPV
vaccine initiation (Du, Camacho, McCall-Hosenfeld, et al.,
2015), this research is particularly relevant for rural health.
In the present study, differences in HPV vaccination
percentages among counties were revealed. Completion
percentages and average time to completion varied within
the SCHD, indicating the individualized needs for each
county. Variation among counties is supported by another
study evaluating HPV vaccination in Georgia, revealing the
importance of a county-level approach to increasing HPV
vaccination (Thomas, Strickland, DiClemente, et al., 2013).
Moving forward, studies of HPV vaccination in rural areas
may benefit from considering county-level differences in
addition to larger population analyses to meet the needs of
the various communities. Because each county has different
healthcare access and delivery challenges, health
departments should be encouraged to incorporate a datadriven approach by planning and allocating resources based
on the documented needs of their specific subpopulations.
However, the most prominent barrier to this approach would
likely be the access to and analysis and interpretation of data
needed for this type of informed decision making.

Limitations included that the information gathered from the
SCHD reflected only individuals who had received at least
one HPV vaccine dose from one of the ten county health
departments. Information regarding adolescents who
received HPV vaccinations from private providers in this
region or who received additional vaccinations without
GRITS documentation was not examined. Furthermore, the
residence of the SCHD clients may not have been within the
county where they received the HPV vaccine. Additionally,
variables assessed were limited to those available in AEGIS
and GRITS, which excluded some behavioral, social,
motivational, and attitudinal variables that would have been
beneficial to evaluate.

Although overall vaccination rates remain low, school-based
programs have shown promise in increasing HPV vaccine
uptake at the community level. HPV vaccine completion
among 11-12 year-old adolescents exceeded 80% in some
areas of the UK and in Australia where school-based
programs provided the vaccine (Brabin, Roberts, Stretch, et
al., 2008; Stretch, 2008; Reeve, De La Rue, Pashen, et al.,
2008; Watson, Shaw, Molchanoff, et al., 2009; Brotherton,
Deeks, Campbell-Lloyd, et al., 2008). However there have
been few studies of school-based programs in the United
States, especially in rural settings. Greater insight into this
field could be beneficial to the SCHD, as well as to Georgia
as a whole. Existing program evaluations showed that
school-based interventions were likely to offer other
vaccines in addition to that for HPV, provide additional
information about vaccination programs, and administer the
vaccinations during regular school hours (Stubbs, 2014;
Won, Middleman, Auslander, et al., 2015; Caskey, Macario,
Johnson, et al., 2013). Further, school-based programs were
encouraged to seek long-term financial support, as
sustainability of the program budget was a noted weakness
(Daley, Kempe, Pyrzanowski, et al., 2014; Hayes, Entzel,
Berger, et al., 2013). In one program evaluation, parents
whose sons did not have regular doctor’s visits were more
comfortable with their son receiving the HPV vaccine at a
school, indicating a possible target population (Reiter,
McRee, Pepper, et al., 2012). Another study assessing
http://www.gapha.org/jgpha/

As a means of increasing vaccine compliance, future areas
of research should focus on why parents or guardians of
adolescents choose to vaccinate their children, especially in
rural areas. Due to comparable findings at the local level,
where overall vaccine uptake and completion was low,
targeted interventions should be implemented with a focus
on high-risk groups such as males. Furthermore, research
could examine the effectiveness of school-based
interventions that encourage an increase in HPV vaccine
compliance in the general adolescent population across
Georgia. Future research could also focus on healthcare
provider training in how to address concerns about HPV
vaccination. Since healthcare providers have great influence
in rural areas, addressing their knowledge and apprehension
in providing vaccine recommendations would be a way to
affect the larger population they serve.
CONCLUSIONS
By conducting a descriptive epidemiological study of HPV
vaccination coverage in the SCHD, we identified
demographic and socioeconomic characteristics of
individuals who may benefit from additional intervention
practices in order to increase uptake and completion of the
HPV vaccine series. These individuals include males, nonWhite clients, and individuals living in counties with low
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located vaccination clinics for adolescents: correlates of
acceptance among parents. J Community Health, 2015,
40(4):660-669.
Gerend M, Shepherd M, Shepherd J. The multidimensional nature
of perceived barriers: global versus practical barriers to HPV
vaccination. Health Psychol, 2013, 32(4): 361-369.
Hayes K, Entzel P, Berger W, Caskey R, Shlay J, Stubbs B, Smith
J, Brewer N. Early lessons learned from extramural school
programs that offer HPV vaccine. J Sch Health, 2013,
83(2):119-126.
Herrero R, González P, Markowitz L. Present status of human
papillomavirus vaccine development and implementation.
Lancet Oncol, 2015, 16(5):e206-216.
Herrero R, Hildesheim A, Rodríguez AC, the Costa Rica Vaccine
Trial (CVT) Group, et al. Rationale and design of a communitybased double-blind randomized clinical trial of an HPV 16 and
18 vaccine in Guanacaste, Costa Rica. Vaccine, 2008, 26(37):
4795-4808.
Krawczyk A, Perez S, King L, Vivion M, Dubé E, Rosberger Z.
Parents’ decision-making about the human papillomavirus
vaccine for their daughters: II. Qualitative results. Human
Vaccines and Immunotherapeutics, 2015, 11(2): 330-336.
Lehtinen M, Paavonen J, Wheeler C, the HPV PATRICIA Study
Group, et al. Overall efficacy of HPV-16/18 ASO4-adjuvanted
vaccine against grade 3 or greater cervical intraepithelial
neoplasia: 4-year end-of-study analysis of the randomized,
double-blind PATRICIA trial. Lancet Oncol, 2012, 13(1):89-99.
Markowitz L, Dunne E, Saraiya M, Lawson H, Chesson H, Unger
E. Quadrivalent human papillomavirus vaccine:
recommendations of the advisory committee on immunization
practices. MMWR, 2007, 56(RR2):1-32.
McCormack P. Quadrivalent human papillomavirus (types 6, 11,
16, 18) recombinant vaccine (gardasil®): a review of its use in
the prevention of premalignant anogenital lesions, cervical and
anal cancers, and genital warts. Drugs, 2014, 74(11):1253–1283.
Moore G, Crosby R, Young A, Charnigo R. Low rates of free
human papillomavirus vaccine uptake among young women.
Sex Health, 2010, 7(3):287-90.
Naud P, Roteli-Martins C, De Carvalho N, et al. Sustained
efficacy, immunogenicity, and safety of the HPV-16/18 ASO4adjuvanted vaccine: Final analysis of a long-term follow-up
study up to 9.4 years post-vaccination. Hum Vaccine
Immunother, 2014, 10(8): 2147 - 2162.
Printz, C. HPV vaccine uptake remains low. Why some
adolescents are not receiving the vaccine, and what can be done
about it. Cancer, 2013, 119(16):2947-48.
Reeve C, De La Rue S, Pashen D, et al. School-based vaccinations
delivered by general practice in rural north Queensland: an
evaluation of a new human papillomavirus vaccination program.
Commun Dis Intell, 2008, 32(1):94-98.
Reiter PL, McRee A, Pepper J, Chantala K, Brewer N. Improving
human papillomavirus vaccine delivery: a national study of
parents and their adolescent sons. J Adolesc Health, 2012,
51(1):32-37.
StataCorp. 2007. Stata Statistical Software: Release 10. College
Station, TX: StataCorp LP.
Stretch R. Implementing a school-based HPV vaccination
programme. Nurs Times, 2008, 104(48):30-33.
Stubbs B. Evaluation of an intervention providing HPV vaccine in
schools. Am J Health Behav, 2014, 38(1):92-102.
Thomas T, DiClemente R, Snell S. Overcoming the triad of rural
health disparities: How local culture, lack of economic
opportunity, and geographic location instigate health disparities.
Health Educ J, 2014, 73(3):285-294.
Thomas T, Strickland O, Diclemente R, Higgins M. An
opportunity for cancer prevention during preadolescence and
adolescence: stopping human papillomavirus (HPV)-related
cancer through HPV vaccination. J Adolesc Health, 2013,
52(5):S60-68.

percentages of HPV vaccine completion. Broad-scale
interventions, such as school-based vaccination programs,
may be an effective method to increase overall vaccine
initiation and completion rates across various demographic
and socioeconomic groups, and especially in rural
communities.
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